Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Grants totalling almost £350,000 will be made to three Oxford University scientists for their research to combat a devastating muscle-wasting condition, a national charity has announced today.

Source: Muscular Dystrophy Campaign press release

Professor Dame Kay Davies, Professor Matthew Wood and Dr Angela Russell will receive the grants for their research projects to improve understanding of or explore potential treatments for Duchenne muscular dystrophy. The grants have been awarded by charity the Muscular Dystrophy Campaign and fellow members of the Duchenne Forum, and will be awarded over a two or four-year period.

One hundred children are born in the UK each year with Duchenne muscular dystrophy. The condition, which almost always affects boys, is caused by the lack of a vital muscle protein and causes muscles to weaken and waste over time, leading to increasing and severe disability. It affects not only the muscles of the limbs, but also those of the heart and lungs, and few of those born with the condition will live to see their 30th birthday.

Professor Dame Kay Davies’ project will build on her previous work attempting to increase levels of a muscle protein which may compensate for that which is lacking in people affected by Duchenne muscular dystrophy. One drug developed for this purpose by Professor Davies and her colleagues is already in clinical trial. Dr Russell’s work will complement Professor Davies’ work and will seek to better understand how this potential treatment could work. Professor Wood will identify ‘biomarkers’, biological indicators that can be used to measure the progression of Duchenne muscular dystrophy, and a patient’s response to future treatments during clinical trials.

The grants are among seven being awarded by the Duchenne Forum, a collaboration established between six charities to accelerate progress in the search for effective treatments and cures for Duchenne muscular dystrophy. The Duchenne Forum charities are the Muscular Dystrophy Campaign, Alex’s Wish, Duchenne Children’s Trust, Duchenne Research Fund, Joining Jack and Harrison’s Fund.

Dr Marita Pohlschmidt, Director of Research for the Muscular Dystrophy Campaign, said: “Following the dedicated fundraising efforts of our supporters, we are delighted to be able to back the vital work of these three highly respected scientists. Duchenne muscular dystrophy is a devastating condition and we will continue to fund a comprehensive programme of research until treatments are found for every single person affected.”

Professor Dame Kay Davies said:  “This grant makes a big difference to us as it allows the continued screening of the cell line we developed with previous funding from the Muscular Dystrophy Campaign. This approach, which is being carried out in collaboration with Dr Angela Russell in the Chemistry department of Oxford University, will allow us to identify novel hits which increase utrophin levels which we can develop as drug leads.”

Professor Matthew Wood said: "We are very grateful that the Muscular Dystrophy Campaign has decided to support this PhD project which looks at the levels of microRNAs for Duchenne muscular dystrophy. These microRNAs are short pieces of RNA which may be detected in blood. Certain microRNAs change following treatment so we want to use them as biomarkers as it provides an easy and non-invasive way of looking at how well a treatment is working. We are hoping to expand on this and find even better biomarkers."

Similar stories

EAVI2020: The Quest for an HIV Vaccine

In this long read published to coincide with International AIDS Day, we explore how an international collaboration – of which the University of Oxford is a key partner – has boosted HIV vaccine research. We thank our partners at Imperial College London for allowing us to reproduce and abridge this article.

Smoking increases the risks of 56 diseases in Chinese adults

Smoking increases the risks of 56 diseases and kills more than one million adults in China each year from 22 different causes, according to new research published in The Lancet Public Health.

Young lives under pressure as global crises hits mental health and well-being – report

The well-being and mental health of young people in low - and middle - income countries have been dramatically affected by the series of crises hitting the world. As the international community continues to struggle with the impact of COVID-19, conflict and climate change, the latest report from the Young Lives project shows a long-running upward trend in young people’s well-being has been sharply reversed alongside widespread anxiety and depression. Young people are less confident about their futures for the first time in the 20-year study.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

First evidence drug resistant bacteria can travel from gut to lung, increasing infection risks

A new Oxford University study released during World Antimicrobial Awareness Week has significant findings on how antimicrobial resistance (AMR) arises and persists. The results, published today in Nature Communications, provide the first direct evidence of AMR bacteria migrating from a patient’s gut microbiome to the lungs, increasing the risk of deadly infections.